Success Metrics

Active Trials

2(25%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

8(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Terminated(3)

Other(3)

Detailed Status

unknown3

Withdrawn3

Recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 1

Trials by Phase

Phase 18 (100.0%)

Trials by Status

recruiting225%

unknown338%

withdrawn338%

Recent Activity

2 active trials

Showing 5 of 8

recruitingphase_1

Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer

NCT05354375

recruitingphase_1

Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma

NCT04969354

unknownphase_1

Clinical Trials (8)

Showing 8 of 8 trials

NCT05354375Phase 1

Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer

Recruiting

NCT04969354Phase 1

Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma

Recruiting

NCT04121273Phase 1

GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC

Unknown

NCT03252171Phase 1

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

Withdrawn

NCT02575261Phase 1

CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients

Withdrawn

NCT02723942Phase 1

CAR-T Cell Immunotherapy for HCC Targeting GPC3

Withdrawn

NCT03638206Phase 1

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Unknown

NCT03013712Phase 1

A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer

Unknown

All 8 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 8